These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33268483)

  • 21. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
    Kim N; Yi E; Lee E; Park HJ; Kim HS
    Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20.
    Charpak-Amikam Y; Kubsch T; Seidel E; Oiknine-Djian E; Cavaletto N; Yamin R; Schmiedel D; Wolf D; Gribaudo G; Messerle M; Cicin-Sain L; Mandelboim O
    Sci Rep; 2017 Aug; 7(1):8661. PubMed ID: 28819195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.
    Lucar O; Sadjo Diallo M; Bayard C; Samri A; Tarantino N; Debré P; Thiébaut R; Brun-Vézinet F; Matheron S; Cheynier R; Vieillard V;
    AIDS; 2019 Jan; 33(1):23-32. PubMed ID: 30325780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
    Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
    J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
    Zhang T; Wu MR; Sentman CL
    J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.
    Herrmann J; Berberich H; Hartmann J; Beyer S; Davies K; Koch J
    J Biol Chem; 2014 Jan; 289(2):765-77. PubMed ID: 24275655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research Advances of A New Co-stimulatory Molecule-B7 Homolog 6--Review].
    Wu FF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):295-8. PubMed ID: 26913440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines.
    Banu N; Riera-Leal A; Haramati J; Ortiz-Lazareno PC; Panikar SS; Bastidas-Ramirez BE; Gutierrez-Silerio GY; Solorzano-Ibarra F; Tellez-Bañuelos MC; Gutierrez-Franco J; Bueno-Topete MR; Pereira-Suarez AL; Del Toro-Arreola S
    BMC Cancer; 2020 Nov; 20(1):1083. PubMed ID: 33172426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.
    Phillips M; Romeo F; Bitsaktsis C; Sabatino D
    Biopolymers; 2016 Sep; 106(5):658-72. PubMed ID: 27216712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.
    Matta J; Baratin M; Chiche L; Forel JM; Cognet C; Thomas G; Farnarier C; Piperoglou C; Papazian L; Chaussabel D; Ugolini S; Vély F; Vivier E
    Blood; 2013 Jul; 122(3):394-404. PubMed ID: 23687088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.
    Salimi M; Xue L; Jolin H; Hardman C; Cousins DJ; McKenzie AN; Ogg GS
    J Immunol; 2016 Jan; 196(1):45-54. PubMed ID: 26582946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential of B7-H6 as a therapeutic target in cancer immunotherapy.
    Mohammadi A; Najafi S; Amini M; Mansoori B; Baghbanzadeh A; Hoheisel JD; Baradaran B
    Life Sci; 2022 Sep; 304():120709. PubMed ID: 35697295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
    Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
    Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The B7 Family Member B7-H6: a New Bane of Tumor.
    Chen Y; Mo J; Jia X; He Y
    Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling.
    Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H
    Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.
    Lipinski B; Arras P; Pekar L; Klewinghaus D; Boje AS; Krah S; Zimmermann J; Klausz K; Peipp M; Siegmund V; Evers A; Zielonka S
    Protein Sci; 2023 Mar; 32(3):e4593. PubMed ID: 36775946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
    Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
    Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.